Innate immune responses to Stenotrophomonas maltophilia in immunocompromised pediatric patients and the effect of taurolidine
Christoph Ha¨rtel*, Tasja Scholz, Marie Kuhn, Meike Bendiks, Wolfgang Go¨pel, Melchior Lauten, Egbert Herting
Received: January 5, 2012 Revised: March 14, 2012 Accepted: June 25, 2012
Corresponding author. Christoph Ha¨rtel. Department of Paediatrics, University of Lu¨beck, Ratzeburger Allee 160, 23538 Lu¨beck, Germany.
E-mail address: email@example.com (C. Ha¨rtel).
Background and purpose:
Stenotrophomonas maltophilia is an emerging pathogen causing invasive infections in immunocompromised pediatric patients, including neonates and pediatric oncology patients. Information on innate immune responses to S. maltophilia and its potential modulation are scarce.
We established an in vitro S. maltophilia whole blood sepsis model and studied the proinflammatory cytokine production of CD14-positive cells by flow cytometry. We compared the cytokine expression of term newborns (n=13) and healthy adults (n=10) and investigated in vitro responses of pediatric oncology patients after recovery from neutropenia (n=10) with healthy adults (n=10). We further evaluated the immunomodulatory role of the amino-acid derivative taurolidine in our in vitro sepsis model.
Proinflammatory cytokine responses to S. maltophilia were largely diminished in the neonatal population. No remarkable differences were noted for cytokine responses between pediatric oncology patients and healthy controls. Taurolidine inhibited immunoglobulin (IL)-6, IL-8 and tumor necrosis factor-alpha expression in a dose dependent-fashion in both, pediatric oncology patients and healthy controls.
Deficient immune responses to S. maltophilia require optimized prevention strategies against infection in immunocompromised patients, including neonates. Taurolidine may be an effective immunomodulatory agent in a clinical setting.
Cytokines, Flow cytometry, Neonates, Neonatology, Oncology, Pediatrics, Stenotrophomonas maltophilia, Taurolidine